MCRB, US81750R2013

Seres Therapeutics stock was last at EUR 2.22 before November 4 earnings

Published on 10/17/2026 at 22:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue was USD 736,000 on June 30, 2026, with USD 15.6 million cash. Seres Therapeutics stock was last at EUR 2.22 on October 16, 2026.

Earnings date and valuation

MarketBeat lists November 4, 2026, as Seres Therapeutics' estimated third-quarter reporting date.
For the second quarter of 2026, revenue was USD 736,000 and earnings per share were USD 0.47.
Seres Therapeutics stock was last at EUR 2.22 at Lang & Schwarz on October 16, 2026 at 10:59 p.m. CEST.
Seres Therapeutics had a USD 24.5 million market capitalization and a negative 1.03 price-to-earnings ratio.

MCRB, US81750R2013, Illustration mit AI erstellt.

Seres Therapeutics is listed for an estimated November 4, 2026, release of its third-quarter results, according to MarketBeat. The company was last at EUR 2.22 at Lang & Schwarz on October 16, 2026 at 10:59 p.m. CEST, after the Xetra session.

Second-quarter figures set the baseline

MarketBeat records second-quarter 2026 revenue of USD 736,000 and earnings per share of USD 0.47. The earnings figure exceeded the cited consensus estimate of minus USD 2.18 by USD 2.65. That comparison gives the November report a demanding reference point, even though the revenue base remains small.

Nasdaq range keeps the valuation in view

On the Nasdaq, Seres Therapeutics was last at USD 2.46 on October 16, 2026 at 4:00 p.m. ET. The same session data put the 52-week range at USD 2.38 to USD 29.98, market capitalization at USD 24.5 million, volume at 38,566 shares and average volume at 64,060 shares.

Valuation and the next date

The price-to-earnings ratio was negative 1.03, while the company had no reported dividend yield. MarketBeat estimates the next earnings announcement for November 4, 2026, before the market opens, with a conference call scheduled for 8:30 a.m. ET. Its consensus points to a loss of USD 1.0050 per share and revenue of USD 6.35 million for the third quarter.

Comparison with peers

Seres Therapeutics (Nasdaq, USD): price-to-earnings ratio negative 1.03, market capitalization USD 24.5 million.
BioLineRx (Nasdaq, USD): minus 1.95 percent, price-to-earnings ratio negative 1.25, market capitalization USD 10.0 million.
BioXcel Therapeutics (Nasdaq, USD): plus 64.22 percent, price-to-earnings ratio negative 0.01, market capitalization USD 2.3 million.

Euro quote after the session

The latest euro quote places Seres Therapeutics at EUR 2.22 at Lang & Schwarz on October 16, 2026 at 10:59 p.m. CEST. The November 4 reporting date is the next calendar marker for the stock.

The further course of trading is shown by the continuously updated real-time quote of Seres Therapeutics stock.